Drug Search Results
More Filters [+]

Oritavancin

Alternative Names: oritavancin, kimyrsa, orbactiv
Latest Update: 2024-02-01
Latest Update Note: Clinical Trial Update

Product Description

Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.  (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1310422)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lithuania | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States

Approved Indications: Gram-Positive Bacterial Infections | Gram-Positive Bacterial Infections

Known Adverse Events: Headache | Pruritus | Abscess | Chills | Diarrhea

Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oritavancin

Countries in Clinic: Bulgaria, Greece, Latvia, Lithuania, Poland, Portugal, Romania, Spain, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Skin Diseases, Bacterial

Phase 1: Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2022-001297-63

P2

Active, not recruiting

Unknown

2026-04-05

ML-ORI-201

P2

Recruiting

Skin Diseases, Bacterial

2025-06-15

24%

ORKIDS

P1

Completed

Other

2021-05-17

Recent News Events